Tag
Pages related to Cardiology.
ELABELA (ELA) is an endogenous peptide signal studied in development and cardiovascular biology. A 2026 study linked lower ELA levels to fetal congenital heart disease and proposed a mitochondria-related mechanism in cardiac progenitor cells.
A study in humans and mice links lower ELABELA (ELA) levels to congenital heart disease and suggests a mitochondria-related mechanism in cardiac development. Promising as a biomarker lead, not a clinical test yet.
A 2026 umbrella review of prior meta-analyses reports GLP‑1 receptor agonists are associated with lower major adverse cardiovascular events and less ‘worsening heart failure’, plus a small improvement in 6‑minute walk distance. Mortality and heart-failure hospitalization results were not clearly improved, and evidence certainty ranged low to moderate.
A new randomized-trial meta-analysis (preprint) finds the ‘hard outcome’ signal in heart failure is not clean, but people with HFpEF and obesity report better symptoms and walk a bit farther on GLP‑1 drugs.